LDP-endostatin N-terminal fusion protein

N-terminal fusion of Lidamycin apoprotein (LDP) to Endostatin (ES). This fusion protein displays anti-angiogenic, anti-metastatic, and anti-oncogenic properties in human lung tumor samples.

Also Known As:

LDP-ES; LDP-endostatin

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Angiogenic Proteins: 403
      - Angiostatic Proteins: 9
        Endostatins: 1431
        LDP-endostatin N-terminal fusion protein: 1
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Angiogenic Proteins: 403
    - Angiostatic Proteins: 9
      - Endostatins: 1431
        LDP-endostatin N-terminal fusion protein: 1

Experts

1.	Fu, Yan: 1 article (10/2013)
2.	Jiang, Wen-guo: 1 article (10/2013)
3.	Li, Liang: 1 article (10/2013)
4.	Li, Yi: 1 article (10/2013)
5.	Lu, Xin-an: 1 article (10/2013)
6.	Luo, Yongzhang: 1 article (10/2013)
7.	Shang, Bo-yang: 1 article (10/2013)
8.	Zhang, Sheng-hua: 1 article (10/2013)
9.	Zhen, Yong-su: 1 article (10/2013)
10.	Zhou, Daifu: 1 article (10/2013)

Related Diseases

1.	Neoplasms (Cancer) 10/15/2013 - "Tissue microarray was used to analyze the binding affinity of LDP, ES or ES-LDP with specimens of human lung tissue and lung tumor. "

Related Drugs and Biologics

1.	endostatin-LDP C-terminal fusion protein